NCT05061940View on ClinicalTrials.gov

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

TerminatedOBSERVATIONAL
Enrollment

22

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

October 11, 2022

Study Completion Date

October 11, 2022

Conditions
Head and Neck CancerMelanomaHPV-Related MalignancyHPV-Related CarcinomaHPV-Related Cervical CarcinomaHPV Positive Oropharyngeal Squamous Cell CarcinomaLung Cancer, Nonsmall CellMelanoma (Skin)
Interventions
DIAGNOSTIC_TEST

Tumor Profiling

Testing TAA and HPV expression. HLA typing.

Trial Locations (3)

37203

Sarah Cannon Cancer Center, Nashville

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

85258

HonorHealth Research Institute, Scottsdale

Sponsors
All Listed Sponsors
lead

Repertoire Immune Medicines

INDUSTRY

NCT05061940 - This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols. | Biotech Hunter | Biotech Hunter